Optune Lua
Novocure, GmbH · Decision date Oct 15, 2024
What did the FDA approve?
FDA records P230042 as an original PMA application. The recorded decision is approval, dated Oct 15, 2024.
FDA approval order statement
Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Anesthesiology
- Decision date
- Oct 15, 2024
Regulatory record facts
- Identifier
- P230042
- Regulatory pathway
- Premarket approval application
- Applicant
- Novocure, GmbH
- Product code
- SDA
- Decision code
- APPR
- Decision date
- Oct 15, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electrical tumor treatment fields for non-small cell lung cancer.
- Applicant
- Novocure, GmbH
- Product code
- SDA
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230042 received
Application receipt date recorded by FDA.
P230042 · FDA decision
APPR
P230042/S010 · Related supplement
Optune Lua
Timeline entries are records held by MedtechLedger for P230042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Optune LuaP230042/S010 | Novocure, GmbH | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Novocure, GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Neuhofstrasse 21, Baar, 6340
Sources and methodology
- Original FDA record: P230042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records